A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension.

Trial Profile

A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Iloperidone (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms REPRIEVE
  • Sponsors Novartis; Vanda Pharmaceuticals
  • Most Recent Events

    • 05 Jul 2016 Results evaluating the safety and effectiveness of iloperidone for the prevention of relapse in schizophrenia published in the CNS Drugs
    • 26 May 2016 Primary endpoint (To determine the efficacy of flexible dosing of iloperidone compared with placebo in relapse prevention with evaluation of patients by psychiatric rating scales.) has been met, as reported in a Vanda Pharmaceuticals media release.
    • 26 May 2016 Status changed from active, no longer recruiting to discontinued as according to a Vanda Pharmaceuticals media release, in a predefined interim analysis conducted after 68 impending relapse events, confirmed the hypothesis that Fanapt was more effective than placebo in relapse preventions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top